儿童急性淋巴细胞白血病:随机急性淋巴细胞白血病国际-Berlin-Frankfurt-Münster 2009试验结果
国际BFM研究组纳入6187例19岁以下儿童急性淋巴细胞白血病患者,用流式细胞术检测微小残留病(MRD)细化危险分组。中危和高危患者随机比较标准IB方案与增强IB方案,前体B细胞ALL中危患者随机比较甲氨蝶呤2 g/m²与5 g/m²。5年无事件生存率和总生存率分别为75.2%±0.6%和82.6%±0.5%,增强IB方案较标准IB方案无优势,甲氨蝶呤2 g/m²可有效预防复发。
要点
- 流式细胞术检测MRD成功用于细化儿童ALL危险分组,82.6%病例可检测。
- 增强IB方案与标准IB方案5年无事件生存率无显著差异(P=.55)。
- 甲氨蝶呤2 g/m²与5 g/m²5年无事件生存率无显著差异(P=.84),2 g/m²可有效预防非高危前体B细胞ALL复发。
核心结论
- 流式细胞术可成功评估MRD;甲氨蝶呤2 g/m²可有效预防非高危前体B细胞ALL复发;增强IB方案较标准IB方案无优势。
研究设计与样本
- 国际Berlin-Frankfurt-Münster(BFM)研究组开展的随机对照试验,纳入6187例19岁以下儿童急性淋巴细胞白血病患者。
- 基于年龄、白细胞计数、不良遗传学异常和形态学治疗反应,用流式细胞术检测的MRD细化既往ALL intercontinental-BFM 2002研究的危险分组定义。
- 中危和高危患者随机分配至标准IB方案组与增强IB方案组;前体B细胞ALL中危患者随机比较甲氨蝶呤2 g/m²与5 g/m²,每2周一次,共四次。
主要发现
- 5年无事件生存率(EFS±SE)和总生存率(OS±SE)分别为75.2%±0.6%和82.6%±0.5%。
- 标危组(n=624)5年EFS和OS分别为90.7%±1.4%和94.7%±1.1%;中危组(n=4111)分别为77.9%±0.7%和85.7%±0.6%;高危组(n=1452)分别为60.8%±1.5%和68.4%±1.4%。
- 流式细胞术检测MRD在82.6%的病例中可获取。
- 随机分配至标准IB方案组(n=1669)与增强IB方案组(n=1620)的5年EFS分别为73.6%±1.2%与72.8%±1.2%(P=.55)。
- 接受甲氨蝶呤2 g/m²(n=1056)与5 g/m²(n=1027)患者的5年EFS分别为78.8%±1.4%与78.9%±1.4%(P=.84)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The International Berlin-Frankfurt-Münster (BFM) study group conducted a study on pediatric acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD) was assessed using flow cytometry (FCM), and the impact of early intensification and methotrexate (MTX) dose on survival was evaluated. PATIENTS AND METHODS: We included 6,187 patients younger than 19 years. MRD by FCM refined the risk group definition previously used in the ALL intercontinental-BFM 2002 study on the basis of age, WBC count, unfavorable genetic aberrations, and treatment response measured morphologically. Patients at intermediate risk (IR) and high risk (HR) were randomly assigned to protocol augmented protocol I phase B (IB) versus IB regimen. MTX doses of 2 versus 5 g/m2 every 2 weeks, four times, were evaluated in precursor B-cell-ALL (pcB-ALL) IR. RESULTS: The 5-year event-free survival (EFS ± SE) and overall survival (OS ± SE) rates were 75.2% ± 0.6% and 82.6% ± 0.5%, respectively. Their values in risk groups were standard risk (n = 624), 90.7% ± 1.4% and 94.7% ± 1.1%; IR (n = 4,111), 77.9% ± 0.7% and 85.7% ± 0.6%; and HR (n = 1,452), 60.8% ± 1.5% and 68.4% ± 1.4%, respectively. MRD by FCM was available in 82.6% of cases. The 5-year EFS rates in patients randomly assigned to protocol IB (n = 1,669) and augmented IB (n = 1,620) were 73.6% ± 1.2% and 72.8% ± 1.2%, respectively (P = .55), while those in patients receiving MTX doses of 2 g/m2 (n = 1,056) and MTX 5 g/m2 (n = 1,027) were 78.8% ± 1.4% and 78.9% ± 1.4%, respectively (P = .84). CONCLUSION: The MRDs were successfully assessed using FCM. An MTX dose of 2 g/m2 was effective in preventing relapse in non-HR pcB-ALL. Augmented IB showed no advantages over the standard IB.[Media: see text].
引用
- Campbell M, Kiss C, Zimmermann M, et al. Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial. J Clin Oncol. 2023. PMID: 37141547. doi:10.1200/JCO.22.01760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。